News/Publications
Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study.
Brandefors L, Melin B, Lindh J, Lundqvist K, Kimby E.
Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee.
Clinical Intergroup
Clinical Intergroup
The ECWM is based on a clinical intergroup connecting all major clinical national study groups such as:
- BNLI
- Czech Myeloma Group
- FIL Italian Intergroup
- FCGCLLWM Group
- GLA/OSHO
- Greek Myeloma Study Group
- HOVON
- Nordic Lymphoma Group
- Portuguese Lymphoma Study Group
- Spanish Study Group
The ECWM is associated with the Australasian Leukaemia & Lymphoma Goup (ALLG). This clinical intergroup forms a unique platform for setting up large clinical and innovative trials in a rare disease such as WM.
Currently several clinical trials are initiated which offer patients with WM novel therapeutic approaches in the setting of well controlled clinical trials.